Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $31.50.
Several research firms recently issued reports on VRDN. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Viridian Therapeutics in a report on Tuesday, July 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price target on shares of Viridian Therapeutics in a report on Tuesday, June 11th. Wolfe Research began coverage on shares of Viridian Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $29.00 price target on the stock. LADENBURG THALM/SH SH cut shares of Viridian Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, May 9th. Finally, B. Riley downgraded Viridian Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the company from $25.00 to $20.00 in a report on Thursday, May 9th.
Read Our Latest Analysis on VRDN
Institutional Trading of Viridian Therapeutics
Viridian Therapeutics Stock Down 0.7 %
Shares of Viridian Therapeutics stock opened at $15.02 on Wednesday. Viridian Therapeutics has a 1-year low of $10.93 and a 1-year high of $24.18. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.99 and a quick ratio of 23.99. The company has a market capitalization of $958.58 million, a PE ratio of -3.34 and a beta of 1.13. The business has a 50-day moving average of $13.76 and a 200-day moving average of $15.55.
Viridian Therapeutics Company Profile
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Further Reading
- Five stocks we like better than Viridian Therapeutics
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- Where Do I Find 52-Week Highs and Lows?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.